By ThinkSabio #ThinkSabio Latest News
AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC has again failed to improve overall survival in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead's Trodelvy significantly improved OS in a prior late-phase study